Creative Planning Scynexis Inc Transaction History

Creative Planning

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	BUY	$1.93 - $3.64 $35,400 - $66,764	18,342 New	18,342 $41,000
Q2 2021 Aug 04, 2021	SELL	$6.5 - $9.97 $193,700 - $297,106	-29,800 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$6.93 - $9.63 $35,343 - $49,113	5,100 Added 20.65%	29,800 $237,000
Q4 2020 Jan 29, 2021	BUY	$4.28 - $7.87 $17,120 - $31,480	4,000 Added 19.32%	24,700 $189,000
Q3 2020 Nov 05, 2020	BUY	$4.37 - $7.48 $90,459 - $154,836	20,700 New	20,700 $91,000

13.2M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $34.9M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.